TOMI Environmental Solns (NASDAQ: TOMZ) delivered a significant acceleration in top-line performance for the second quarter of 2026, reporting revenue of $2.25 million. This figure represents a 118% increase compared to $1.03 million in the same period last year and a 36% sequential rise from the first quarter of 2026. The growth was primarily fueled by robust demand for its SteraMist decontamination technology, specifically in BIT Solution sales and capital equipment deployments.

Financial Performance

The company demonstrated strong operating leverage during the quarter. Gross profit more than doubled to $1.39 million, reflecting a gross margin expansion to 61.7% from 50.3% in the prior quarter. This margin improvement was attributed to higher revenue volumes and an optimal mix of high-margin consumable sales alongside equipment deployments.

Operating expenses were managed effectively, declining 10% year-over-year to $1.63 million. This reduction was led by savings in general and administrative costs, partially offset by approximately $300,000 in transaction-related professional fees associated with the pending merger with Carbonium Core. Consequently, the operating loss narrowed significantly by 78% to approximately $244,000, down from $1.13 million in Q2 2025.

The net loss for the quarter improved by 69% to approximately $382,000, or $0.05 per basic and diluted share, compared to a net loss of $1.24 million ($0.19 per share) in Q2 2025. All per-share figures reflect the 1-for-3 reverse stock split effected on July 20, 2026.

What the Numbers Show

A critical divergence exists between the company's operational trajectory and its net loss profile. While the operating loss contracted sharply by 78%, indicating improving core business efficiency, the net loss reduction was slightly less pronounced at 69%. This suggests that non-operating items or tax effects may have influenced the bottom line. Furthermore, the expansion in gross margin to 61.7% alongside a 118% revenue surge highlights the scalability of the "razor-and-blade" model, where high-margin applicator sales ($355,000 in Q2, up from $13,000 in Q2 2025) are locking in long-term recurring demand for BIT Solutions.

Balance Sheet and Liquidity

Liquidity positions strengthened during the quarter. Cash and cash equivalents rose to $322,000 from $88,000 at year-end 2025, supported by $1.92 million in net proceeds from the equity line of credit (ELOC). Working capital expanded to $1.82 million from $1.02 million at the end of 2025. Stockholders' equity increased significantly to $1.43 million, up from $589,000 as of June 30, 2025. The company maintains approximately $18.1 million in remaining contractual capacity under its ELOC facility.

Operational Highlights and Backlog

The sales order backlog grew steadily, reaching $2.2 million at quarter-end and expanding to $2.6 million post-quarter. Management highlighted several key operational milestones:

• Medical Device Sector: Delivery of SteraMist IHP chambers to a Fortune 500 medical device manufacturer, advancing the 510(k) clearance process with the FDA.
• Regulatory Approvals: Expanded EU registrations to include Austria, Italy, Germany, and others. Secured new EPA registration for AgriMist, allowing direct application on indoor-grown plants and fruits up to harvest day.
• Strategic Merger: Continued integration planning with Carbonium Core, which includes a $10 million minimum concurrent financing condition prior to closing.

Management reaffirmed full-year 2026 revenue guidance of at least $12 million, citing a robust pipeline of approximately $35 million and strong execution across domestic and international markets.

TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ) reaffirmed its expectation to achieve revenue of at least $12 million in 2026, signaling confidence in its growth trajectory following a robust first half. The disinfection and decontamination solutions provider reported that sales in the first half of 2026 increased by over 100% compared to the same period in 2025, already exceeding the full-year sales figure for 2025. This performance underpins the company’s current financial outlook and validates its strategic expansion efforts across international markets and new sectors.

The company currently holds $6.2 million in booked orders and orders expected to be completed before year-end. Additionally, approximately $8.6 million of its total $35 million sales pipeline is in advanced stages. In the second quarter of 2026, all four key metrics—BIT Solution sales, mobile equipment sales, single applicator sales, and support services—demonstrated both year-over-year and sequential growth. Management attributed the increases in applicator sales and support services to initiatives implemented in late 2024 and early 2025.

Strategic Mergers and Partnerships

TOMI remains actively engaged with Carbonium Core following the signing of a definitive merger agreement, with plans to close the transaction in the second half of 2026. The merger marks a strategic pivot into the nuclear materials sector, leveraging Carbonium’s pilot study for producing nuclear-grade graphite for 4th-generation nuclear reactors, supported by the U.S. Department of Energy.

Internationally, TOMI expanded its SteraMist registrations across the European Union, securing approvals in Austria, Italy, the Netherlands, Belgium, Denmark, Germany, Hungary, Spain, Great Britain, and Northern Ireland. The company added Switzerland through an amendment and anticipates further approvals in France, Ireland, Poland, Portugal, and Romania. In Poland, a partnership with MedLine will enable marketing under the DeconLine brand pending mutual recognition. Other key partnerships include collaborations in Germany, the United Kingdom, and the Netherlands, as well as an active deployment in Israel to support Ebola containment efforts.

Sector Expansion and Regulatory Advances

The company is pursuing growth in emerging markets such as robotaxis, biosecurity, drones, and humanoid robotics. In the defense sector, TOMI received approvals from contractors in Korea and agencies in Canada, alongside ongoing engagements with U.S. government agencies including USAMRIID, NIH, and Aberdeen. A partnership with The Defense Logistics Agency (DLA) aims to streamline procurement of SteraMist iHP Technology.

Regulatory progress includes TOMI’s role in advancing Biosafety Cabinet (BSC) decontamination standards with NSF International. The industry is shifting toward performance-based criteria, favoring SteraMist iHP technology over legacy methods like paraformaldehyde. Key pipeline opportunities include a near-$1 million project for a major medical company and a Custom Engineered System valued at approximately $1 million.

What the Numbers Show

The doubling of first-half sales compared to 2025 indicates a significant acceleration in commercial adoption, likely driven by the expanded European regulatory approvals and defense sector entries. The presence of $8.6 million in advanced pipeline stages relative to the $12 million annual guidance suggests a high conversion rate is required to meet targets, highlighting the critical nature of closing current bids such as the Canadian Hybrid Systems opportunity.

Elissa J. Shane, Chief Operating Officer, stated, "We are pleased with the continued momentum across the SteraMist iHP business... TOMI is executing well on multiple fronts." Dr. Halden Shane, Chairman and CEO, emphasized the strategic importance of the Carbonium merger, noting the accelerating demand for nuclear graphite due to global decarbonization efforts.